XOMA Royalty Declares Quarterly Preferred Stock Dividends

1 week ago

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has…

SweetWater Brewing Announces 28th Anniversary Bash With STS9 Headlining an Immersive Jamtronica Experience

1 week ago

HoliBlaze Ticket Promotion Now Available for the February 22nd SweetWater Anniversary PartyATLANTA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- SweetWater Brewing…

Altimmune Added to Nasdaq Biotechnology Index

1 week ago

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it…

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI 

1 week ago

Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12,…

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

1 week ago

Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech…

Microbix Reports Record Product Sales for Q4 and Fiscal 2024

1 week ago

Full-Year Revenues of $25.4 million and Net Income of $3.5 millionMISSISSAUGA, Canada, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems…

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

1 week ago

ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies…

NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate

1 week ago

KdT has formed a new company to develop NGM313 in a rare disease indicationNGM Bio will receive up to $608…

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

1 week ago

Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2…

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

1 week ago

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept…